SIRT1 Inhibition Affects Angiogenic Properties of Human MSCs

Botti Chiara, Caiafa Ilaria, Coppola Antonietta, Cuomo Francesca, Miceli Marco, Altucci Lucia, Cobellis Gilda

Research output: Contribution to journalArticle

Abstract

Humanmesenchymal stem cells (hMSCs) are attractive for clinical and experimental purposes due to their capability of self-renewal and of differentiating into several cell types. Autologous hMSCs transplantation has been proven to induce therapeutic angiogenesis in ischemic disorders. However, themolecular mechanisms underlying these effects remain unclear. A recent report has connected MSCsmultipotency to sirtuin families, showing that SIRT1 can regulate MSCs function. Furthermore, SIRT1 is a criticalmodulator of endothelial angiogenic functions. Here, we described the generation of an immortalized human mesenchymal bone marrowderived cell line and we investigated the angiogenic phenotype of our cellular model by inhibiting SIRT1 by both the genetic and pharmacological level. We first assessed the expression of SIRT1 in hMSCs under basal and hypoxic conditions at both RNA and protein level. Inhibition of SIRT1 by sirtinol, a cell-permeable inhibitor, or by specific sh-RNA resulted in an increase of prematuresenescence phenotype, a reduction of proliferation rate with increased apoptosis. Furthermore, we observed a consistent reduction of tubule-like formation and migration and we found that SIRT1 inhibition reduced the hypoxia induced accumulation of HIF-1 protein and its transcriptional activity in hMSCs. Our findings identify SIRT1 as regulator of hypoxia-induced response in hMSCs andmay contribute to the development of new therapeutic strategies to improve regenerative properties ofmesenchymal stem cells in ischemic disorders through SIRT1 modulation.

Original languageEnglish
Article number783459
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

Stem cells
Stem Cells
RNA
Phenotype
Stem Cell Transplantation
Proteins
Pharmacology
Apoptosis
Bone
Bone and Bones
Cell Line
Cells
Modulation
Therapeutics
Hypoxia

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Chiara, B., Ilaria, C., Antonietta, C., Francesca, C., Marco, M., Lucia, A., & Gilda, C. (2014). SIRT1 Inhibition Affects Angiogenic Properties of Human MSCs. BioMed Research International, 2014, [783459]. https://doi.org/10.1155/2014/783459

SIRT1 Inhibition Affects Angiogenic Properties of Human MSCs. / Chiara, Botti; Ilaria, Caiafa; Antonietta, Coppola; Francesca, Cuomo; Marco, Miceli; Lucia, Altucci; Gilda, Cobellis.

In: BioMed Research International, Vol. 2014, 783459, 2014.

Research output: Contribution to journalArticle

Chiara, B, Ilaria, C, Antonietta, C, Francesca, C, Marco, M, Lucia, A & Gilda, C 2014, 'SIRT1 Inhibition Affects Angiogenic Properties of Human MSCs', BioMed Research International, vol. 2014, 783459. https://doi.org/10.1155/2014/783459
Chiara B, Ilaria C, Antonietta C, Francesca C, Marco M, Lucia A et al. SIRT1 Inhibition Affects Angiogenic Properties of Human MSCs. BioMed Research International. 2014;2014. 783459. https://doi.org/10.1155/2014/783459
Chiara, Botti ; Ilaria, Caiafa ; Antonietta, Coppola ; Francesca, Cuomo ; Marco, Miceli ; Lucia, Altucci ; Gilda, Cobellis. / SIRT1 Inhibition Affects Angiogenic Properties of Human MSCs. In: BioMed Research International. 2014 ; Vol. 2014.
@article{399c5558d1e048ba98c5d0cfd7c012bf,
title = "SIRT1 Inhibition Affects Angiogenic Properties of Human MSCs",
abstract = "Humanmesenchymal stem cells (hMSCs) are attractive for clinical and experimental purposes due to their capability of self-renewal and of differentiating into several cell types. Autologous hMSCs transplantation has been proven to induce therapeutic angiogenesis in ischemic disorders. However, themolecular mechanisms underlying these effects remain unclear. A recent report has connected MSCsmultipotency to sirtuin families, showing that SIRT1 can regulate MSCs function. Furthermore, SIRT1 is a criticalmodulator of endothelial angiogenic functions. Here, we described the generation of an immortalized human mesenchymal bone marrowderived cell line and we investigated the angiogenic phenotype of our cellular model by inhibiting SIRT1 by both the genetic and pharmacological level. We first assessed the expression of SIRT1 in hMSCs under basal and hypoxic conditions at both RNA and protein level. Inhibition of SIRT1 by sirtinol, a cell-permeable inhibitor, or by specific sh-RNA resulted in an increase of prematuresenescence phenotype, a reduction of proliferation rate with increased apoptosis. Furthermore, we observed a consistent reduction of tubule-like formation and migration and we found that SIRT1 inhibition reduced the hypoxia induced accumulation of HIF-1 protein and its transcriptional activity in hMSCs. Our findings identify SIRT1 as regulator of hypoxia-induced response in hMSCs andmay contribute to the development of new therapeutic strategies to improve regenerative properties ofmesenchymal stem cells in ischemic disorders through SIRT1 modulation.",
author = "Botti Chiara and Caiafa Ilaria and Coppola Antonietta and Cuomo Francesca and Miceli Marco and Altucci Lucia and Cobellis Gilda",
year = "2014",
doi = "10.1155/2014/783459",
language = "English",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - SIRT1 Inhibition Affects Angiogenic Properties of Human MSCs

AU - Chiara, Botti

AU - Ilaria, Caiafa

AU - Antonietta, Coppola

AU - Francesca, Cuomo

AU - Marco, Miceli

AU - Lucia, Altucci

AU - Gilda, Cobellis

PY - 2014

Y1 - 2014

N2 - Humanmesenchymal stem cells (hMSCs) are attractive for clinical and experimental purposes due to their capability of self-renewal and of differentiating into several cell types. Autologous hMSCs transplantation has been proven to induce therapeutic angiogenesis in ischemic disorders. However, themolecular mechanisms underlying these effects remain unclear. A recent report has connected MSCsmultipotency to sirtuin families, showing that SIRT1 can regulate MSCs function. Furthermore, SIRT1 is a criticalmodulator of endothelial angiogenic functions. Here, we described the generation of an immortalized human mesenchymal bone marrowderived cell line and we investigated the angiogenic phenotype of our cellular model by inhibiting SIRT1 by both the genetic and pharmacological level. We first assessed the expression of SIRT1 in hMSCs under basal and hypoxic conditions at both RNA and protein level. Inhibition of SIRT1 by sirtinol, a cell-permeable inhibitor, or by specific sh-RNA resulted in an increase of prematuresenescence phenotype, a reduction of proliferation rate with increased apoptosis. Furthermore, we observed a consistent reduction of tubule-like formation and migration and we found that SIRT1 inhibition reduced the hypoxia induced accumulation of HIF-1 protein and its transcriptional activity in hMSCs. Our findings identify SIRT1 as regulator of hypoxia-induced response in hMSCs andmay contribute to the development of new therapeutic strategies to improve regenerative properties ofmesenchymal stem cells in ischemic disorders through SIRT1 modulation.

AB - Humanmesenchymal stem cells (hMSCs) are attractive for clinical and experimental purposes due to their capability of self-renewal and of differentiating into several cell types. Autologous hMSCs transplantation has been proven to induce therapeutic angiogenesis in ischemic disorders. However, themolecular mechanisms underlying these effects remain unclear. A recent report has connected MSCsmultipotency to sirtuin families, showing that SIRT1 can regulate MSCs function. Furthermore, SIRT1 is a criticalmodulator of endothelial angiogenic functions. Here, we described the generation of an immortalized human mesenchymal bone marrowderived cell line and we investigated the angiogenic phenotype of our cellular model by inhibiting SIRT1 by both the genetic and pharmacological level. We first assessed the expression of SIRT1 in hMSCs under basal and hypoxic conditions at both RNA and protein level. Inhibition of SIRT1 by sirtinol, a cell-permeable inhibitor, or by specific sh-RNA resulted in an increase of prematuresenescence phenotype, a reduction of proliferation rate with increased apoptosis. Furthermore, we observed a consistent reduction of tubule-like formation and migration and we found that SIRT1 inhibition reduced the hypoxia induced accumulation of HIF-1 protein and its transcriptional activity in hMSCs. Our findings identify SIRT1 as regulator of hypoxia-induced response in hMSCs andmay contribute to the development of new therapeutic strategies to improve regenerative properties ofmesenchymal stem cells in ischemic disorders through SIRT1 modulation.

UR - http://www.scopus.com/inward/record.url?scp=84922513541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922513541&partnerID=8YFLogxK

U2 - 10.1155/2014/783459

DO - 10.1155/2014/783459

M3 - Article

C2 - 25243179

AN - SCOPUS:84922513541

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 783459

ER -